Iniparib (BSI-201) structure
|
Common Name | Iniparib (BSI-201) | ||
|---|---|---|---|---|
| CAS Number | 160003-66-7 | Molecular Weight | 292.031 | |
| Density | 2.1±0.1 g/cm3 | Boiling Point | 344.8±32.0 °C at 760 mmHg | |
| Molecular Formula | C7H5IN2O3 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 162.3±25.1 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Iniparib (BSI-201)Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer. |
| Name | 4-Iodo-3-nitrobenzamide |
|---|---|
| Synonym | More Synonyms |
| Description | Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer. |
|---|---|
| Related Catalog | |
| Target |
PARP1 |
| In Vitro | Iniparib nonselectively modifies cysteine-containing proteins in tumor cells[1]. Iniparib (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1[2]. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes[3]. |
| Cell Assay | For nine day cell proliferation assay, MDA-MB-436 and MDA-MB-231 cells are plated at 2000 and 500 cells/well respectively in a 96-well plate and treated with veliparib, cmpd-A, cmpd-C, Iniparib or Iniparib-met at 0, 0.0001, 0.01,0.1, 1 or 10 μM for nine days. For five day cell proliferation assay, MDAMB-231 and MDA-MB-436 cells are plated at 1000 and 4000 cells/well respectively in a 96-well plate and treated with Iniparib or Iniparib-met at 0. 0.1, 0.3, 1, 3 or 10 μM in the presence of 0, 1.8, 3.75, or 7.5 µM BSO for 5 days. DLD1+/+ and DLD1-/- cells are plated at 1000 cells/well in a 96-well plate and treated with TMZ at 0, 0.003, 0.01, 0.03, 0.1, 0.3 or 1 mM in the presence of 0, 0.005, 0.05, 0.5, or 5 µM veliparib, or Iniparib for five days. After treatment, cell titer glow is carried out[1]. |
| References |
| Density | 2.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 344.8±32.0 °C at 760 mmHg |
| Molecular Formula | C7H5IN2O3 |
| Molecular Weight | 292.031 |
| Flash Point | 162.3±25.1 °C |
| Exact Mass | 291.934479 |
| PSA | 88.91000 |
| LogP | 1.71 |
| Appearance of Characters | white to beige |
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
| Index of Refraction | 1.696 |
| Storage condition | room temp |
| Water Solubility | DMSO: soluble5mg/mL, clear |
|
~81%
Iniparib (BSI-201) CAS#:160003-66-7 |
| Literature: DIVI'S LABORATORIES LIMITED; Divi, Murali Krishna Prasad; Rao, Mysore Aswatha Narayana; Rajuri, Venkataramana Patent: US2013/172618 A1, 2013 ; Location in patent: Paragraph 0027; 0028 ; |
|
~39%
Iniparib (BSI-201) CAS#:160003-66-7 |
| Literature: Octamer, Inc. Patent: US5877185 A1, 1999 ; |
|
~54%
Iniparib (BSI-201) CAS#:160003-66-7 |
| Literature: Cant, Alastair A.; Bhalla, Rajiv; Pimlott, Sally L.; Sutherland, Andrew Chemical Communications, 2012 , vol. 48, # 33 p. 3993 - 3995 |
|
~%
Iniparib (BSI-201) CAS#:160003-66-7 |
| Literature: Journal of Organic Chemistry, , vol. 62, # 10 p. 3093 - 3097 |
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
| Iniparib (BSI-201) |
| 4-Iodo-3-nitrobenzamide |
| Benzamide, 4-iodo-3-nitro- |
| Iniparib |
| BSI-201 |